Staging of the Axilla in Breast Cancer and the Evolving Role of Axillary Ultrasound

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Axillary lymph nodes have long been recognized as a route for breast cancer to spread systemically. As a result, staging of the axilla has always played a central role in the treatment of breast cancer. Anatomic staging was believed to be important for two reasons: 1) it predicts prognosis and guides medical therapy, and 2) it is a potential therapy for removal of disease in the axilla. This paradigm has now been called into question. Prognostic information is driven increasingly by tumor biology, and trials such as the ACOSOG Z0011 demonstrates removal of axillary disease is not therapeutic. Staging of the axilla has undergone a dramatic de-escalation; however, sentinel lymph node biopsy (SLNB) is still an invasive surgery and represents a large economic burden on the healthcare system. In this review, we outline the changing paradigms of axillary staging in breast cancer from emphasis on anatomic staging to tumor biology, and the evolving role of axillary ultrasound, bringing patients less invasive and more personalized therapy.

Related collections

Most cited references 86

Record: found
Abstract: found
Article: not found

Cancer Statistics, 2021

Rebecca Siegel, Kimberly D Miller, Hannah Fuchs … (2021)

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2017) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2018) were collected by the National Center for Health Statistics. In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. After increasing for most of the 20th century, the cancer death rate has fallen continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment. This translates to 3.2 million fewer cancer deaths than would have occurred if peak rates had persisted. Long-term declines in mortality for the 4 leading cancers have halted for prostate cancer and slowed for breast and colorectal cancers, but accelerated for lung cancer, which accounted for almost one-half of the total mortality decline from 2014 to 2018. The pace of the annual decline in lung cancer mortality doubled from 3.1% during 2009 through 2013 to 5.5% during 2014 through 2018 in men, from 1.8% to 4.4% in women, and from 2.4% to 5% overall. This trend coincides with steady declines in incidence (2.2%-2.3%) but rapid gains in survival specifically for nonsmall cell lung cancer (NSCLC). For example, NSCLC 2-year relative survival increased from 34% for persons diagnosed during 2009 through 2010 to 42% during 2015 through 2016, including absolute increases of 5% to 6% for every stage of diagnosis; survival for small cell lung cancer remained at 14% to 15%. Improved treatment accelerated progress against lung cancer and drove a record drop in overall cancer mortality, despite slowing momentum for other common cancers.

0 comments Cited 6813 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Molecular portraits of human breast tumours.

Charles Perou, Therese Sørlie, Michael B. Eisen … (2000)

Human breast tumours are diverse in their natural history and in their responsiveness to treatments. Variation in transcriptional programs accounts for much of the biological diversity of human cells and tumours. In each cell, signal transduction and regulatory systems transduce information from the cell's identity to its environmental status, thereby controlling the level of expression of every gene in the genome. Here we have characterized variation in gene expression patterns in a set of 65 surgical specimens of human breast tumours from 42 different individuals, using complementary DNA microarrays representing 8,102 human genes. These patterns provided a distinctive molecular portrait of each tumour. Twenty of the tumours were sampled twice, before and after a 16-week course of doxorubicin chemotherapy, and two tumours were paired with a lymph node metastasis from the same patient. Gene expression patterns in two tumour samples from the same individual were almost always more similar to each other than either was to any other sample. Sets of co-expressed genes were identified for which variation in messenger RNA levels could be related to specific features of physiological variation. The tumours could be classified into subtypes distinguished by pervasive differences in their gene expression patterns.

0 comments Cited 1447 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Radiomics: the bridge between medical imaging and personalized medicine

Seán Froudist Walsh, Joachim Wildberger, Felix Mottaghy … (2017)

Radiomics, the high-throughput mining of quantitative image features from standard-of-care medical imaging that enables data to be extracted and applied within clinical-decision support systems to improve diagnostic, prognostic, and predictive accuracy, is gaining importance in cancer research. Radiomic analysis exploits sophisticated image analysis tools and the rapid development and validation of medical imaging data that uses image-based signatures for precision diagnosis and treatment, providing a powerful tool in modern medicine. Herein, we describe the process of radiomics, its pitfalls, challenges, opportunities, and its capacity to improve clinical decision making, emphasizing the utility for patients with cancer. Currently, the field of radiomics lacks standardized evaluation of both the scientific integrity and the clinical relevance of the numerous published radiomics investigations resulting from the rapid growth of this area. Rigorous evaluation criteria and reporting guidelines need to be established in order for radiomics to mature as a discipline. Herein, we provide guidance for investigations to meet this urgent need in the field of radiomics.

0 comments Cited 1431 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (nlm-ta): Breast Cancer (Dove Med Press)

Journal ID (iso-abbrev): Breast Cancer (Dove Med Press)

Journal ID (publisher-id): bctt

Journal ID (pmc): bctt

Title: Breast Cancer : Targets and Therapy

Publisher: Dove

ISSN (Electronic): 1179-1314

Publication date (Electronic): 17 May 2021

Publication date Collection: 2021

Volume: 13

Pages: 311-323

Affiliations

[1 ]Department of Surgery, Washington University , St Louis, MS, USA

[2 ]Siteman Cancer Center in St. Louis , St Louis, MS, USA

Author notes

Correspondence: William E Gillanders Siteman Cancer Center in St. Louis , 660 South Euclid Avenue Campus Box 8109, St Louis, MS, 63110, USATel +1 314 747 0072 Email gillandersw@wustl.edu

Article

Publisher ID: 273039

DOI: 10.2147/BCTT.S273039

PMC ID: 8139849

SO-VID: ef547e08-e9ba-4954-ad76-e131b8113839

License:

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

History

Date received : 11 March 2021

Date accepted : 23 April 2021

Page count

Figures: 4, Tables: 2, References: 90, Pages: 13

Funding

Funded by: Washington University School of Medicine Surgical Oncology Basic Science and Translational Research Training Program;

This publication was supported by the Washington University School of Medicine Surgical Oncology Basic Science and Translational Research Training Program grant T32CA009621. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Staging of the Axilla in Breast Cancer and the Evolving Role of Axillary Ultrasound

Read this article at

Abstract

Related collections

Karger: Oncology

Most cited references 86

Cancer Statistics, 2021

Molecular portraits of human breast tumours.

Radiomics: the bridge between medical imaging and personalized medicine

Author and article information

Journal

Affiliations

Author notes

Article

History

Page count

Funding

Categories

Comments

Comment on this article

Similar content 579

Cited by 2

Most referenced authors 2,276